Software Equity Group

APRIL 4, 2023

Refined Target Audiences As the business organically grew and we added acquisitions to our portfolio, the marketing team needed to refine its target audience and identify our ideal customer profile (ICP) for new segments. I regularly share insights and trends aimed at boosting valuations and facilitating smoother exits.

Sale 52

Sale Book-building Business M&A 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. approved prescription cannabidiol medicine to its portfolio. billion to enhance product diversification by adding the first and only FDA?approved

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

DECEMBER 20, 2024

While questions around the ultimate buyers of these organizations have been building, the sale of RCA, the largest retina practice portfolio in the U.S., And many of their existing owners will pursue acquisition opportunities in the interim to grow before a sale and hopefully achieve a higher exit valuation.

Private Equity 52

Private Equity Healthcare Equities Sale 52

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64